Cantor Fitzgerald analyst Joseph France reiterated a Hold rating on CRH Medical Corporation (NYSE: CRHM) today and set a price target of $3. The company’s shares opened today at $3.45, close to its 52-week high of $3.75.
France noted:
“We are reiterating our $3 price target and Neutral rating, and tweaking our estimates to reflect a recent acquisition and the company’s 2Q18 results. CRH’s 2Q18 numbers were below our estimates on a lack of acquisitions, but it closed one in late July that will help 3Q18. CRH completed $21 million of acquisitions year to date, and we expect it could complete almost $15 million more. We continue to believe that the company’s outlook depends primarily upon on its ability to precipitate a consolidation of the industry.”
According to TipRanks.com, France is a 5-star analyst with an average return of 11.2% and a 59.5% success rate. France covers the Services sector, focusing on stocks such as Cross Country Healthcare, Five Star Quality Care, and US Physical Therapy.
CRH Medical Corporation has an analyst consensus of Hold, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
Based on CRH Medical Corporation’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $1.43 million. In comparison, last year the company had a GAAP net loss of $493.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CRH Medical Corp. engages in the provision of gastroenterologists with innovative services and products for the treatment of gastrointestinal diseases. It offers CRH O’Regan System, which focuses on physician education, patient outcomes, and patient awareness. The company was founded in 2000 and is headquartered in Vancouver, Canada.
